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-xtraction Ratio of Cyclosporine in a Liver Transplant III" 
lient with Organ Rejection t:> IIrT ' .. , 
To the bditor~ clearance value compares well with the mean (:: SD) blood 
Cyciosporine, a cyclic polypeptide with potent immunosup- clearance of 8.4 (:: 3.6) mUminikg estimated in 10 pediatric 
pressive properties,' has been successfully used to prevent liver transplant patients subsequent to an intravenous jnfu-
the rejection of transplanted organa such as kidneys, livers, ajon of cyclosporine.' These intravenous studiu were con-
heans, and bone marrowK~ It is highly lipophilic and is dw:ted within 10 d after . transplant. It is likely that the I eliminated primarily by metabolism in the ·liver.- Recent metabolizing ability of the liver would improve with time 
I studies in transplant patients indicate c:yclosporiDe to be a and that one might observe a higher cyclosporine clearanc:e low-t.o-intermediate clearance drug. We had a unique oppor- ill a clinically stable patient.' " •. 'c'. 
tanity to directly determine the hepatic atrac:tion ratio of . From the above obsenation. it appears that c:yclosporine is 
this cIrui in a pediatric liver transplant recipient. . a.drug with a low-to-medium extraction ratio. In the present 
The patient was a 40-year-old male who underwent liver atudy, the extraction ratio wudetermined at a amcentration 
transplantation for at-antitrypsin deficiency. Subsequent to or 500-600 n.gImL of. c:yclosporine. The extrution.ratio of 
his first transplantation, he progresaeci well until 1 month certain drugs are concentration dependent. Presently, there 
following 51U'gery when he developed hepatic artery throm- . is no eYidence to Illggest that cyclosporine undergoesnonlin-
bosia. He received a second liver 63 d after the.1irst trans-ear elimiDation kinetics in humans when admmjstved in 
: plant. On the day prior to the second transPlant, the liver lberapeutic dales. It should aIao be realized thaub emac-
. function tests were as followa: .Jk.)jne phosphatase, 63 lUlL; tian ratio or c:yclosporiDawaa c:alculated in .,.Jfnr with 
: IIInlm glutamic ouloacetic tnml8Dlin 'M (SGOT), 8M lUlL; hepatic arterytbrombosia It is not known to wbatu:teDt the 
,
: Ie1'Um glutamic pyruvic trans·mine (SGPr), 273 lUlL; bili- metabolizing capacity or the liver will be altereliby hepatic 
rubin (total), 1.0 mgldL; bilirubin (direct), 0.2 mgldL. This artery thrombosis. In additioD. the effect of c:hmaic-immuno-
. D~icated that the patient did not have a normally function- nppressive therapy with c:yclosporin.e and a low daM of 
liver. The patient did not receive any drup known to pndnisolone on cyclosporine metabolism is not bownat the 
lDduce or inhibit the drug-metabolizing eDZJ1II8 syatema of patMJit time. In any ~ the fact that qdosporine is 
the liver at any time prior to the I8CIDIId transplant. At the Primarily metabolized in the live!' and that it is a drarwith 
time of the study, the patient received c:yclosporine and a low Iow-to-intennediat extraction indicates that ita: cJeennce 
. dose of prednisolone as UnmUlUllUpplrisents, captopril for can he altered significantly by c:haDPs in tha.·iDtrinsic 
thetrutment of hypertension, and QBtemic aatibiotics. ... c1earam:e and blood proteiD. hind;ng and to a IIIIid18r eztent 
Prior to the operation, 30 mgimofsecabarbital waa.dndni.. by c:banps ill the liver blood flow. Recent Itadi8s have 
tered.Just prior to the removal of the first tnmaplantedliver, reported increased metabo1ism of CJdosporine bLpatienta 
Iimultaneolll blood samples were obtained £rom the hepatic . treated with phenytoin, phenobarbital, or mUDpin, which 
and portal veins. Blood samples .... kept frozen until '. are .knoWu to induce cirug-metabolizing e~ltp:Dheto-
analyzed for whole blood c:yclosporiDe concentration by conazol8y which. is known to inhibit drug-met;ab01i iin .. en-
HPLC. . . zymes, has also been reported to increase c:yclosporiDe,blood 
The bl~ was extracted using the procedure of Sa,Rhuck levels in kidney transplant patients. 13 In cam:bilion, the 
~ CartIer.' Samples were analyzed using a R~IKKm C1I presentobsenationagreeswiththerecentstudiaiDdicating 
Cll~ E~upelcoI Bellefonte, PAl .heated .to 70"C and UV cydosporine to be a drug with low-to-intermed.Wedearance. 
cetectlon tmodel441; Waters Associates, Milford, MAl at 214 ., 
nm.. Standards were prepared in blank blood, and the inter-
nal standard was cyc:losporine D (Sandoz Pharmaceuticals. 
Basel. S\\;tzerlandl. The mobUe phase was 6890 acetonitrile, 
delivered at 1.8 mUmin. Under these conditions, the reten-
tion tiro ~ for c:yclosporine was 9.8 min and that for cyclospor-
ine 0 \\ as 12.Smin. The CV of the analytical method was 
3.95% at 600 nglmL (n - 10), The concentration of cyelospor-
ine in the portal vein CPv) was 596 ngimL. whereas the 
he~Ptic vein \ HV) concentration was 500 ngimL. The hepatic 
er=:;.ction ratio was: 
H . E . Ra· PV-HV ep:l.t1c xtractlon tl0 - pv -= 0.161 
.1 t!-.:s J;st:ent, the first transplanted liver was 740 g in 
wtig:'t. The hepatic blood flow inhUIDallS is 100 mLlI00 i of 
live:- v'eight.' Therefore, baled on an estimated blood dow or 
7';0 cl.. one ~would predict a .. cyc:lasporine clearance of 119:~ 
r::.:L=..i:l or 7.6 IX'.Lminikg in:this patient.TFiia. predicted 
, . y' Y·,-', ~~"KC ~~;D::~I~~ 
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